Related references
Note: Only part of the references are listed.Detection of unknown primary neuroendocrine tumours (CUP-NET) using Ga-68-DOTA-NOC receptor PET/CT
Vikas Prasad et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid
Valentina Ambrosini et al.
NUCLEAR MEDICINE COMMUNICATIONS (2009)
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET
Stefano Fanti et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
Valentina Ambrosini et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Ga-68-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors
C. Pettinato et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Processing of generator-produced 68Ga for medical application
Konstantin P. Zhernosekov et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
I. Buchmann et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
P. Antunes et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
68Ga-DOTATATE PET in neuroectodermal tumours:: First experience
Zarni Win et al.
NUCLEAR MEDICINE COMMUNICATIONS (2007)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Results of individual patient dosimetry in peptide receptor radionuclide therapy with Lu-177 DOTA-TATE and Lu-177 DOTA-NOC
Christiane Wehrmann et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2007)
Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours
K Öberg et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours
G Kaltsas et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals
D Wild et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Neuroendocrine tumor targeting:: Study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model
S Froidevaux et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
